EP Patent

EP3628682A1 — Formulations of glucagon-like-peptide-2 (glp-2) analogues

Assigned to Zealand Pharma AS · Expires 2020-04-01 · 6y expired

What this patent protects

Stable liquid pharmaceutical formulation of glucagon-like-peptide-2 (GLP-2) analogues are disclosed and their medical use, for example in the treatment and/or prevention of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy…

USPTO Abstract

Stable liquid pharmaceutical formulation of glucagon-like-peptide-2 (GLP-2) analogues are disclosed and their medical use, for example in the treatment and/or prevention of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy. More particularly, liquid formulations of GLP-2 analogues are described that comprise a preservative and that can be stabilised for long term storage as liquids and/or as multi-dose liquid formulations.

Drugs covered by this patent

Patent Metadata

Patent number
EP3628682A1
Jurisdiction
EP
Classification
—
Expires
2020-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Zealand Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.